<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454362</url>
  </required_header>
  <id_info>
    <org_study_id>QMUL111111</org_study_id>
    <secondary_id>2011-005565-20</secondary_id>
    <secondary_id>U1111-1127-4445</secondary_id>
    <nct_id>NCT01454362</nct_id>
  </id_info>
  <brief_title>Effect of the Electronic Cigarette on Withdrawal Symptoms</brief_title>
  <acronym>ECIG24</acronym>
  <official_title>Phase 4 Study to Compare of the Effects of the Electronic Cigarette and Nicotine Inhalator on Tobacco Withdrawal Symptoms Over 24 Hours of Abstinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study rationale: Sensory/behavioural elements of smoking play a role in smoking behaviour and
      may have a potential to assist smoking cessation. Among current treatments for smokers, only
      the nicotine inhalator is attempting to address such factors. The inhalator's efficacy does
      not exceed that of the other nicotine replacement therapy (NRT) products, but it mimics the
      relevant sensory input to only a limited extent, and its nicotine delivery is dependent on
      intensive puffing. Recently a new product, the Electronic Cigarette (E-C) has become
      available, which provides a more realistic behaviour and sensory replacement for smoking and
      can provide good nicotine levels with less effort.

      Primary objective: To compare E-C and nicotine inhalator in their effects on tobacco
      withdrawal symptoms over 24hr abstinence.

      Hypotheses: E-C will be more effective than the inhalator in reducing withdrawal symptoms and
      craving and elicit more favorable user ratings. It will also provide higher nicotine levels.

      Study design: In a cross-over study, participants will be randomized to the sequence of
      conditions and provide baseline measures and samples for salivary cotinine analysis. They
      will be asked to abstain from smoking their usual cigarettes and use the allocated product
      over 24 hours. They will return to the study centre the following day, and complete measures
      of craving and withdrawal, ratings of subjective and sensory effects of the products, product
      satisfaction, and adverse effects. They will also provide saliva samples for cotinine
      analysis. Abstinence from smoking will be verified with CO readings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is considerable interest in E-Cs at the moment and the study would provide information
      on whether the E-C surpasses the tried and tested nicotine inhalator. If so, it would open a
      possibility of its utilization in smoking cessation, and provide encouragement for further
      examination of the role of sensorimotor replacements in the treatment of tobacco dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of E-C and Inhalator in Effects on Withdrawal Over 24 Hours of Use.</measure>
    <time_frame>24 hours</time_frame>
    <description>Mood and Physical Symptoms Scale (MPSS): Measure of severity of urges to smoke and tobacco withdrawal symptoms.
A five-point scale is used to rate 'How much of the time have you felt the urge to smoke in the past week?' ((1) 'not at all' to (5) 'almost all of the time') and 'How strong have the urges been?' ('no urges' to 'very strong'). Clients also rate depression, irritability, restlessness, hunger, poor concentration, poor sleep at night, and anxiety during the past week ((1)=not at all to (5)=extremely). The combined score to questions on depression, irritability, restlessness, hunger, and poor concentration are averaged to give the MPSS score. A higher score means a more severe rating of withdrawal.
The primary outcome is a change in MPSS score between baseline and 24 hours (value at 24 hours minus value at baseline). Therefore, a smaller change in MPSS score represents a smaller increase in tobacco withdrawal symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Salivary Cotinine Levels After 24-hour Use.</measure>
    <time_frame>24 hours</time_frame>
    <description>Cotinine is a measure sensitive enough to detect effects of a switch to different nicotine products and salivary cotinine was shown to be dependent on nicotine mouth exposure.
The results show the mean change in salivary cotinine in each study arm (all study participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinforcing Effects of Smoking</measure>
    <time_frame>24 hours</time_frame>
    <description>Modified Cigarette Evaluation Questionnaire (mCEQ): Measure of reinforcing effects of smoking (pleasant feeling). Mean pleasant feeling from using product (rating 0-4). Higher value indicating the higher rating of pleasure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Sensations</measure>
    <time_frame>24 hours</time_frame>
    <description>Sensory effects: Measure of airway sensations (throat and chest). Mean enjoyment score (rating 0-4), higher the score indicating increased enjoyment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>Product satisfaction: Ratings of product satisfaction (when compared to cigarettes). Rating 0-4, with higher value indicating higher satisfaction ratings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Mental and Behavioral Disorders</condition>
  <condition>Withdrawal State</condition>
  <arm_group>
    <arm_group_label>Electronic cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Inhalator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Inhalation of nicotine.</description>
    <arm_group_label>Electronic cigarette</arm_group_label>
    <arm_group_label>Nicotine Inhalator</arm_group_label>
    <other_name>Nicorette inhalator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers smoking at least 12 cigarettes per day

          -  First cigarette smoked within 60 minutes of waking up

          -  Willing to abstain from smoking for one day in 2 consecutive weeks.

        Exclusion Criteria:

          -  Under 18 years of age

          -  Current psychiatric illness

          -  Pregnant or breastfeeding

          -  Enrollment in other research projects

          -  Used electronic cigarette and/or nicotine inhalator before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayden J McRobbie, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tobacco Dependence Research Unit</name>
      <address>
        <city>London</city>
        <zip>E1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl). 2004 Dec;177(1-2):195-9. Epub 2004 Jun 4.</citation>
    <PMID>15179542</PMID>
  </reference>
  <reference>
    <citation>West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med. 1989 Nov;19(4):981-5.</citation>
    <PMID>2594893</PMID>
  </reference>
  <reference>
    <citation>Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Multivariate framework of the Brief Questionnaire of Smoking Urges. Drug Alcohol Depend. 2007 Oct 8;90(2-3):234-42. Epub 2007 May 7.</citation>
    <PMID>17482773</PMID>
  </reference>
  <reference>
    <citation>Rose JE, Behm FM, Westman EC, Bates JE, Salley A. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacol Biochem Behav. 2003 Sep;76(2):243-50.</citation>
    <PMID>14592675</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <results_first_submitted>September 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2019</results_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary University of London</investigator_affiliation>
    <investigator_full_name>Hayden McRobbie</investigator_full_name>
    <investigator_title>Reader in Public Health Interventions</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>inhalator</keyword>
  <keyword>electronic cigarette</keyword>
  <keyword>tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the Tobacco Dependence Research Unit in London between January 2013 and February 2013.</recruitment_details>
      <pre_assignment_details>Inclusion Criteria Smoking at least 12 cigarettes per day; first cigarette smoked within 60 mins of waking; willing to abstain from smoking for one day in 2 consecutive weeks.
Exclusion Criteria Under 18s; current psychiatric illness; planning pregnancy, pregnant or breastfeeding; enrolled in other research; used EC or inhaler before.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Electronic Cigarette Then, Nicotine Inhalator</title>
          <description>Randomised to receive electronic cigarette at the first session. Tested at study session then given to use ad-lib over 24 hours. Participants then returned to the clinic.
1 week wash out period.
Asked to return to clinic to receive Nicotine Inhalator. Tested at clinic then given product to use ad-lib over 24 hours. Participants then returned to the clinic.
Nicotine: Inhalation of nicotine.</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Inhalator Then, Electronic Cigarette</title>
          <description>Randomised to receive Nicotine Inhalator at the first session. Tested at study session then given to use ad-lib over 24 hours. Participants then returned to the clinic.
1 week wash out period.
Asked to return to clinic to receive electronic cigarette. Tested at clinic then given product to use ad-lib over 24 hours. Participants then returned to the clinic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was randomised crossover trial</population>
      <group_list>
        <group group_id="B1">
          <title>Electronic Cigarette First, Then Nicotine Inhalator</title>
          <description>Randomised to receive electronic cigarette at the first session. Tested at study session then given to use ad-lib over 24 hours. Participants then returned to the clinic.
1 week wash out period.
Asked to return to clinic to receive Nicotine Inhalator. Tested at clinic then given product to use ad-lib over 24 hours. Participants then returned to the clinic.</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Inhalator First, Then Electronic Cigarette</title>
          <description>Randomised to receive Nicotine Inhalator at the first session. Tested at study session then given to use ad-lib over 24 hours. Participants then returned to the clinic.
1 week wash out period.
Asked to return to clinic to receive electronic cigarette. Tested at clinic then given product to use ad-lib over 24 hours. Participants then returned to the clinic.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of E-C and Inhalator in Effects on Withdrawal Over 24 Hours of Use.</title>
        <description>Mood and Physical Symptoms Scale (MPSS): Measure of severity of urges to smoke and tobacco withdrawal symptoms.
A five-point scale is used to rate 'How much of the time have you felt the urge to smoke in the past week?' ((1) 'not at all' to (5) 'almost all of the time') and 'How strong have the urges been?' ('no urges' to 'very strong'). Clients also rate depression, irritability, restlessness, hunger, poor concentration, poor sleep at night, and anxiety during the past week ((1)=not at all to (5)=extremely). The combined score to questions on depression, irritability, restlessness, hunger, and poor concentration are averaged to give the MPSS score. A higher score means a more severe rating of withdrawal.
The primary outcome is a change in MPSS score between baseline and 24 hours (value at 24 hours minus value at baseline). Therefore, a smaller change in MPSS score represents a smaller increase in tobacco withdrawal symptoms.</description>
        <time_frame>24 hours</time_frame>
        <population>Reporting group</population>
        <group_list>
          <group group_id="O1">
            <title>Electronic Cigarette</title>
            <description>All study participants.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Inhalator</title>
            <description>All study participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of E-C and Inhalator in Effects on Withdrawal Over 24 Hours of Use.</title>
          <description>Mood and Physical Symptoms Scale (MPSS): Measure of severity of urges to smoke and tobacco withdrawal symptoms.
A five-point scale is used to rate 'How much of the time have you felt the urge to smoke in the past week?' ((1) 'not at all' to (5) 'almost all of the time') and 'How strong have the urges been?' ('no urges' to 'very strong'). Clients also rate depression, irritability, restlessness, hunger, poor concentration, poor sleep at night, and anxiety during the past week ((1)=not at all to (5)=extremely). The combined score to questions on depression, irritability, restlessness, hunger, and poor concentration are averaged to give the MPSS score. A higher score means a more severe rating of withdrawal.
The primary outcome is a change in MPSS score between baseline and 24 hours (value at 24 hours minus value at baseline). Therefore, a smaller change in MPSS score represents a smaller increase in tobacco withdrawal symptoms.</description>
          <population>Reporting group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.64"/>
                    <measurement group_id="O2" value="0.86" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Salivary Cotinine Levels After 24-hour Use.</title>
        <description>Cotinine is a measure sensitive enough to detect effects of a switch to different nicotine products and salivary cotinine was shown to be dependent on nicotine mouth exposure.
The results show the mean change in salivary cotinine in each study arm (all study participants).</description>
        <time_frame>24 hours</time_frame>
        <population>Reporting group</population>
        <group_list>
          <group group_id="O1">
            <title>Electronic Cigarette</title>
            <description>All study participants.
We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
Nicotine: Inhalation of nicotine.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Inhalator</title>
            <description>All study participants.
The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
Nicotine: Inhalation of nicotine.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Salivary Cotinine Levels After 24-hour Use.</title>
          <description>Cotinine is a measure sensitive enough to detect effects of a switch to different nicotine products and salivary cotinine was shown to be dependent on nicotine mouth exposure.
The results show the mean change in salivary cotinine in each study arm (all study participants).</description>
          <population>Reporting group</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.32" spread="94.84"/>
                    <measurement group_id="O2" value="-53.8" spread="119.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reinforcing Effects of Smoking</title>
        <description>Modified Cigarette Evaluation Questionnaire (mCEQ): Measure of reinforcing effects of smoking (pleasant feeling). Mean pleasant feeling from using product (rating 0-4). Higher value indicating the higher rating of pleasure.</description>
        <time_frame>24 hours</time_frame>
        <population>Reporting group</population>
        <group_list>
          <group group_id="O1">
            <title>Electronic Cigarette</title>
            <description>All study participants.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Inhalator</title>
            <description>All study participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Reinforcing Effects of Smoking</title>
          <description>Modified Cigarette Evaluation Questionnaire (mCEQ): Measure of reinforcing effects of smoking (pleasant feeling). Mean pleasant feeling from using product (rating 0-4). Higher value indicating the higher rating of pleasure.</description>
          <population>Reporting group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1.11"/>
                    <measurement group_id="O2" value="0.67" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Sensations</title>
        <description>Sensory effects: Measure of airway sensations (throat and chest). Mean enjoyment score (rating 0-4), higher the score indicating increased enjoyment.</description>
        <time_frame>24 hours</time_frame>
        <population>Reporting group</population>
        <group_list>
          <group group_id="O1">
            <title>Electronic Cigarette</title>
            <description>All study participants.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Inhalator</title>
            <description>All study participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Sensations</title>
          <description>Sensory effects: Measure of airway sensations (throat and chest). Mean enjoyment score (rating 0-4), higher the score indicating increased enjoyment.</description>
          <population>Reporting group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="1.05"/>
                    <measurement group_id="O2" value="0.51" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Satisfaction</title>
        <description>Product satisfaction: Ratings of product satisfaction (when compared to cigarettes). Rating 0-4, with higher value indicating higher satisfaction ratings.</description>
        <time_frame>24 hours</time_frame>
        <population>Reporting group</population>
        <group_list>
          <group group_id="O1">
            <title>Electronic Cigarette</title>
            <description>All study participants.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Inhalator</title>
            <description>All study participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Satisfaction</title>
          <description>Product satisfaction: Ratings of product satisfaction (when compared to cigarettes). Rating 0-4, with higher value indicating higher satisfaction ratings.</description>
          <population>Reporting group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="1.05"/>
                    <measurement group_id="O2" value="0.59" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours after product use</time_frame>
      <desc>Adverse effects questionnaire (adapted from Hajek et al, 1989)</desc>
      <group_list>
        <group group_id="E1">
          <title>Electronic Cigarette</title>
          <description>All study participants used product.</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Inhalator</title>
          <description>All study participants used product.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairement</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbances in attention</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Hayden McRobbie</name_or_title>
      <organization>Queen Mary University of London</organization>
      <phone>0207 882 7260</phone>
      <email>researchamendments@bartsandthelondon.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

